Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria.
about
Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuriaEculizumab for treating patients with paroxysmal nocturnal hemoglobinuriaTherapeutic regulation of complement in patients with renal disease - where is the promise?Platelets in inflammation and atherogenesisA humanized antibody that regulates the alternative pathway convertase: potential for therapy of renal disease associated with nephritic factorsIdiopathic combined, autoantibody-mediated ADAMTS-13/factor H deficiency in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in a 17-year-old woman: a case report.Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE studyParoxysmal nocturnal hemoglobinuriaHemoglobinuria misidentified as hematuria: review of discolored urine and paroxysmal nocturnal hemoglobinuria.Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient miceSafety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial.Paroxysmal nocturnal hemoglobinuria (PNH): higher sensitivity and validity in diagnosis and serial monitoring by flow cytometric analysis of reticulocytes.Complement-mediated haemolysis and the role of blood transfusion in paroxysmal nocturnal haemoglobinuria.Predictive Factors of Mortality in Population of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results from a Korean PNH Registry.Investigational treatments for multiple myeloma.Presentation and Management of Paroxysmal Nocturnal Hemoglobinuria: A Single-Center Experience.Complement in immune and inflammatory disorders: therapeutic interventions.Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria.Prevention of experimental autoimmune myasthenia gravis by rat Crry-Ig: A model agent for long-term complement inhibition in vivoRationale for anti-CD200 immunotherapy in B-CLL and other hematologic malignancies: new concepts in blocking immune suppression.Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria.Anticomplement therapy.The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab.Development of a disease-specific quality of life questionnaire for patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria (QLQ-AA/PNH)-report on phases I and II.Autoimmune hemolytic anemia: classification and therapeutic approaches.Eculizumab opens a new era of treatment for paroxysmal nocturnal hemoglobinuria.Mechanisms and clinical implications of thrombosis in paroxysmal nocturnal hemoglobinuria.Eculizumab: a review of its use in paroxysmal nocturnal haemoglobinuria.Paroxysmal nocturnal hemoglobinuria and the age of therapeutic complement inhibition.Presence of acute and chronic renal failure in patients with paroxysmal nocturnal hemoglobinuria: results of a retrospective analysis from the Spanish PNH Registry.Targeting the complement cascade: novel treatments coming down the pike.Paroxysmal Nocturnal Hemoglobinuria: From Bench to Bed.Complementopathies.Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan.Cross-sectional validation study of patient-reported outcomes in patients with paroxysmal nocturnal haemoglobinuria.Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization.A New Approach for the Treatment of Arthritis in Mice with a Novel Conjugate of an Anti-C5aR1 Antibody and C5 Small Interfering RNA.Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes.Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases.Paroxysmal nocturnal hemoglobinuria: pathophysiology, natural history and treatment options in the era of biological agents.
P2860
Q24193045-835B9A13-EB93-43AD-A606-AD5430E6525BQ24201126-241CA117-411D-4926-B799-298DC09DCDBDQ26851705-5E7C41D7-99E7-41BE-BD63-270F3C3445A6Q28085020-1FA40F9C-9FAC-4417-B5CC-86ECEAB8A12BQ30409539-18D73607-4DDC-4DB0-98F6-01F0CBE0F43CQ33398967-97E886B6-3046-40AB-A9C6-192952FAA2F3Q33586908-4F8DAAD2-230C-4C5B-96D5-777C4AC580E7Q34431429-FEADEB99-9D25-46DA-9309-565DCEE09B47Q34462881-07B081BA-C34C-4A3C-92FF-EB64F642D278Q34537391-F654BE01-2824-42DD-B502-B76FD24EC9ABQ34626253-1976D6C9-8193-4C3A-9C8C-36B3024DA670Q35093962-D9F6B387-023E-4E4A-BC57-F7CEBE7B55B3Q36187306-01AC29AF-2BBD-4482-B312-0A2BCCB498FBQ36509944-284D996E-5ACD-4A04-AA04-ED515387BF32Q36654336-11630672-0A3E-4A84-A000-77204DB629B9Q36751227-8F40FE94-85B2-4A5A-8C3E-85BF1819DEC8Q36756854-C05D2FA9-03A2-458C-BD1E-A9B943FD0258Q36780187-2315F975-A418-40DD-BD07-9AE007610EA4Q36947184-EA9A8152-0393-43B5-A281-F0536EFF4CD6Q37032625-47024ADE-318D-49EB-A80E-1C11DA7E6AD2Q37098212-015DDCF0-CA11-4883-936C-421B66F1E031Q37307880-97911358-C4C9-4FEF-917A-7CD41D5D6503Q37462959-830EE1DB-A28F-4972-A51F-558B7EF7627CQ37580829-CDEAB50E-9D7D-4299-9471-4CE52A7D0DC7Q37810065-4E4C8B34-0A1C-4D32-A39A-6A292C7941DEQ37810103-0DB99FE4-F4E6-492B-A135-A77D6EDE2603Q37955206-68B309C8-CE20-4A2D-B8DC-4D9171D3331BQ37956407-04102BB1-9603-4300-9F08-BFBF48A58006Q38156229-D204196D-F702-42B9-B083-8A8E557ACEBDQ38658582-E11786A6-E745-4C3B-8840-9713BD31B933Q38850489-C3D76B71-2409-4699-AE5C-8735DE4F065FQ38998217-CB1E1576-8BF8-44E2-867B-469F6A2FCC9AQ39142842-2AB5DD3F-6418-4F2D-BDE5-C80150A42DDCQ39554119-DF70185D-A346-4E27-BA44-2F2621CE536CQ39566121-27EC264E-6DA6-4325-973C-F6F7AD5D64B9Q40107597-68E9EB74-1A10-49D2-9B3E-0F945CDDB289Q40734548-C5D9EDCF-4009-4F21-A922-8AE2FFC7EAB0Q41091207-0D914D80-D56A-4104-AED2-F4EB05DF61D0Q41953134-7209611B-DE90-4EB0-B0A4-4D25AEB4A6EAQ42036462-14D8BF26-ACC0-4082-B69F-F4C89864107A
P2860
Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Sustained response and long-te ...... smal nocturnal hemoglobinuria.
@ast
Sustained response and long-te ...... smal nocturnal hemoglobinuria.
@en
Sustained response and long-te ...... smal nocturnal hemoglobinuria.
@en-gb
Sustained response and long-te ...... smal nocturnal hemoglobinuria.
@nl
type
label
Sustained response and long-te ...... smal nocturnal hemoglobinuria.
@ast
Sustained response and long-te ...... smal nocturnal hemoglobinuria.
@en
Sustained response and long-te ...... smal nocturnal hemoglobinuria.
@en-gb
Sustained response and long-te ...... smal nocturnal hemoglobinuria.
@nl
prefLabel
Sustained response and long-te ...... smal nocturnal hemoglobinuria.
@ast
Sustained response and long-te ...... smal nocturnal hemoglobinuria.
@en
Sustained response and long-te ...... smal nocturnal hemoglobinuria.
@en-gb
Sustained response and long-te ...... smal nocturnal hemoglobinuria.
@nl
P2093
P1433
P1476
Sustained response and long-te ...... smal nocturnal hemoglobinuria.
@en
P2093
Anita Hill
Christopher F Mojcik
Dupe Elebute
Jason Chan
Judith C Marsh
Russell P Rother
Stephen J Richards
P304
P356
10.1182/BLOOD-2005-02-0564
P407
P577
2005-06-28T00:00:00Z